REVIEW
|
doi:10.20944/preprints202307.0430.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
Hodgkin lymphoma; relapsed/refractory; brentuximab vedotin; checkpoint inhibitor; PD-1 inhibitor; nivolumab; pembrolizumab; autologous hematopoietic cell transplantation
Online: 6 July 2023 (11:44:13 CEST)